title: [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].
abstract: Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a week after last receiving the peptide. Selank had a positive impact on the quality of life of the patients. Conclusion. The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders.
authors.forename: V E
authors.initials: VE
authors.lastname: Medvedev
authors.forename: O N
authors.initials: ON
authors.lastname: Tereshchenko
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Israelian
authors.forename: I K
authors.initials: IK
authors.lastname: Chobanu
authors.forename: N V
authors.initials: NV
authors.lastname: Kost
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Sokolov
authors.forename: N F
authors.initials: NF
authors.lastname: Miasoedov
mesh_terms: D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D014151:Anti-Anxiety Agents; D009842:Oligopeptides; D001569:Benzodiazepines; C017928:phenazepam; C100827:TP 7